The FDA has agreed to fast-track its review of gepotidacin, an oral antibiotic already approved for urinary tract infections, for the treatment of uncomplicated gonorrhea.
The UK's National Health Service is offering the 4CMenB vaccine, which provides cross-protection against gonorrhea, to patients at the greatest risk of infection.
A genomic analysis finds the percentage of US gonorrhea isolates carrying tetracycline resistance genes rose from 10% in 2020 to more than 30% in 2024.
A review and meta-analysis of data from 51 countries shows median tetracycline resistance in the bacterium that causes gonorrhea is 54%.
Doxycycline post-exposure prophylaxis isn't formally available in the Netherlands, but 23% of respondents to an online survey said they've used it.
Drugmaker Innoviva said the FDA has accepted its new drug application for zoliflodacin, an investigational oral antibiotic for uncomplicated gonorrhea.
Two novel antibiotic candidates for gonorrhea received funding to advance into clinical trials.
Starting in August, eligible patients can receive shots of 4CMenB, a vaccine for meningococcal B disease that provides moderate cross-protection against gonorrhea.
Two systematic reviews and meta-analyses found evidence that OMV-based meningococcal B vaccines offer moderate cross-protection.
A study at a sexual health clinic finds that significant declines in chlamydia and syphilis were sustained nearly 2 years after doxy-PEP was introduced.
